Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Table 2 Least squares mean changes from baseline to end-point in lower urinary tract symptoms/benign prostatic hyperplasia in clinical studies for treatment in subjects with erectile dysfunction and without erectile dysfunction

Ref.	Drug	Remarks	Total IPSS		IPSS voiding subscore		IPSS storage subscore		IPSS QoL subscore		BII		Qmax		IIEF
	mg		T	P	T	P	T	P	T	P	T	P	T	P	T	P
	Tadalafil
Brock et al[39]	5	ED	-5.7	-3.3	-3.5	-1.9	-2.2	-1.3	-1.1	-0.7	-1.6	-0.9
	5	No ED	-5.4	-3.3	-3.5	-2	-1.9	-1.3	-1		-1.4	-1
Dmochowski et al[13]	20		-9.2	-5.1	-5.6	-2.8	-3.6	-2.3					0.4	0.5
Donatucci et al[14]	2.5		-5.7	-4.1	-3.8	-2.5	-1.9	-1.6	-1.2	-0.9	-1.3	-1.2			5.5	7.2
	5		-5.0		-2.8		-2.1		-1.1		-1.4				5.3
	10		-5.7		-3.6		-1.8		-1.3		-1.4				3.7
	20		-4.6		-3		-2.1		-1		1.2				7.6
Egerdie et al[15]	2.5		-6.1	-3.8	-2.7	-2.2	-1.9	-1.6	-0.9	-0.8	-2.1	-1.2			6.5	1.8
	5		-4.6		-3.6		-2.5		-1		-1.6				5.2
Kim et al[16]	5		-5.6	-3.6									2.5	2.3
McVary et al[18]	5		-6.2	-3.9	-4	-2.5	-2.2	-1.4	-0.7	-0.3	-0.7	-0.4	0.5	0.9	6.7	0.7
	5/20		-7.1	-4.5	-4.4	-2.8	-2.7	-1.8	-0.5	-0.2	-1.3	-0.6	0.5		8.4	1.6
Oelke et al[19]	5		-6.3	-4.2	-4.1	-2.6	-2.2	-1.6	-1.3	-1			2.4	1.2
Porst et al[21]	2.5		-4.2	-2.1											8.2	2
	5		-4.7												7.9
	10		-4.7												6.8
	20		-3.6												5.4
Porst et al[36]	5		-5.6	-3.6	-3.3	-2.3	-2.3	-1.3			-1.8	-1.3			6.7	2
Porst et al[20]	5		-7.9	-5.1
Roehrborn et al[22]	2.5		-5.17	-2.27	-2.94	-1.26	-1.96	-0.99	-0.92	-0.49	-1.38	-0.83	1.96	1.24	8.34	2.2
	5		-3.88		-2.23		-2.07		-0.88		-1.4		1.41		7.98
	10		-5.21		-3.12		-1.58		-0.74		-0.96		1.64		6.97
	20		-4.87		-3.13		-1.89		-0.86		-1.45		1.58		5.59
Roehrborn et al[12]	5	Qmax < 10	-5.2	-3.6	-3.2	-2.1							2.8	2.4
	5	Qmax of 10-15	-6.3	-3.8	-3.9	-2.5							1.4	0.9
	5	Qmax > 15	-6.8	-2.7	-3.9	-1.2							-1.1	-2.7
Takeda et al[24]	5		-6	-4.5	-2	-1.4	-2	-1.4	-2	-1.4
Yokoyama et al[25]	2.5		-5	-3	-3.3	-1.9	-1.7	-1.1	-0.8	-0.5	-1	-0.8	1.3	2.1
	5		-5.1		-3.72		-1.5		-0.8		-1.1		1.6
	Sildenafil
McVary et al[10]	50		-6.3	-1.9					-0.9	-0.3	-2	-0.9	0.31	0.16	9.17	1.86
	100
	Vardenafil
Stief et al[40]	10		-5.8	-3.6									1.6	1

IIEF: International index of erectile function; IPSS: International prostate symptom; Qmax: Maximum urinary flow rate; QoL: Quality of life; BII: Benign prostatic hyperplasia impact index; ED: Erectile dysfunction; T: Treatment; P: Placebo.